跳至主要内容
临床试验/NCT07657013
NCT07657013已完成不适用

Effect of Transcutaneous Stellate Ganglion Electrical Stimulation on Restless Leg Syndrome in Hemodialysis Patients

Cairo University1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年10月10日最近更新:
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
36
试验地点
1
主要终点
International Restless Leg Syndrome Rating Scale (IRLS)

研究概览

简要总结

This randomized controlled trial investigated the effect of transcutaneous stellate ganglion electrical nerve stimulation (TENS-SG) on restless legs syndrome (RLS) in patients undergoing hemodialysis. Thirty-six patients aged 40-50 years were randomly assigned to two equal groups: Group A received active TENS-SG applied over the cervical-thoracic (stellate ganglion) region three times weekly for four weeks, while Group B received placebo stimulation.

The study evaluated multiple outcomes including RLS severity (IRLS scale), sleep quality (PSQI), quality of life (SF-12), pain perception (pressure pain threshold), blood pressure, psychological status (HADS), and plasma β-endorphin levels.

Results demonstrated that TENS-SG significantly reduced RLS severity and improved sleep quality, pain threshold, quality of life, and psychological well-being compared to placebo. It also significantly reduced systolic and diastolic blood pressure and markedly increased β-endorphin levels.

Overall, the findings suggest that TENS-SG is a safe, non-invasive, and effective intervention for improving neurological, cardiovascular, psychological, and quality-of-life outcomes in hemodialysis patients with RLS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
40 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 36 patients will be involved in this study according to the following criteria
  • Patient undergoes four main clinical criteria for the diagnosis of RLS according to the international restless leg syndrome study group (IRLSSG) including
  • an urge to move legs that is usually associated with paresthesia.
  • alleviation of the symptoms by moving the legs.
  • aggravation or exacerbation of the symptoms particularly at rest or during sitting or lying down in the bed.
  • worsening of the signs at night.
  • Male and Female patients.
  • The age will range from 40-50 years old.
  • BMI (Body Mass Index 25-34.9 kg/m2
  • Patients with grade 2 Hypertension (160-179/100-109 mmHg)
  • Hemodialysis patients for at least 1year and have restless leg syndrome (RLS).

排除标准

  • History of Deep venous thrombosis
  • History of Bleeding disorders
  • Have an implantable device like a pacemaker
  • Recent Infected wound
  • History of allergic response to the electrodes, gel or tape
  • patients who participating in any other exercise program
  • Loss of sensation or numbness

研究组 & 干预措施

TENS Group

Experimental

Patients will receive transcutaneous stellate ganglion stimulation three times per week for four weeks in addition to standard care

干预措施: transcutaneous electrical nerve stimulation (TENS) (Device)

Sham Stimulation Control Group

Placebo Comparator

Patients will receive a placebo (sham) TENS intervention with electrodes applied but no electrical stimulation (zero intensity), in addition to standard care

干预措施: Sham transcutaneous electrical nerve stimulation (Device)

结局指标

主要结局

International Restless Leg Syndrome Rating Scale (IRLS)

时间窗: Baseline and 4 weeks after treatment

Assessment of restless legs syndrome severity using the International Restless Legs Syndrome Rating Scale. The scale consists of 10 items with a total score ranging from 0 to 40, where higher scores indicates greater symptoms severity (worse outcome).

次要结局

  • Short Form-12 Health Survey (SF-12)(Baseline and 4 weeks after treatment)
  • Pittsburgh Sleep Quality Index (PSQI)(Baseline and 4 weeks after treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Samar Mohamed Mohamed Mabrouk

Senior physiotherapist at El Kasr El Ainy Hospitals

Cairo University

研究点 (1)

Loading locations...

相似试验